CN1249053C - 抗溃疡药物硝酸盐 - Google Patents

抗溃疡药物硝酸盐 Download PDF

Info

Publication number
CN1249053C
CN1249053C CNB998035343A CN99803534A CN1249053C CN 1249053 C CN1249053 C CN 1249053C CN B998035343 A CNB998035343 A CN B998035343A CN 99803534 A CN99803534 A CN 99803534A CN 1249053 C CN1249053 C CN 1249053C
Authority
CN
China
Prior art keywords
nitrate
free valency
salt
ulcer
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998035343A
Other languages
English (en)
Chinese (zh)
Other versions
CN1291982A (zh
Inventor
P·德尔索达托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nicox SA
Original Assignee
Nicox SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox SA filed Critical Nicox SA
Publication of CN1291982A publication Critical patent/CN1291982A/zh
Application granted granted Critical
Publication of CN1249053C publication Critical patent/CN1249053C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/44Acylated amino or imino radicals
    • C07D277/48Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB998035343A 1998-03-05 1999-02-25 抗溃疡药物硝酸盐 Expired - Fee Related CN1249053C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI98A000442 1998-03-05
IT98MI000442A IT1299198B1 (it) 1998-03-05 1998-03-05 Sali nitrati di farmaci antiulcera

Publications (2)

Publication Number Publication Date
CN1291982A CN1291982A (zh) 2001-04-18
CN1249053C true CN1249053C (zh) 2006-04-05

Family

ID=11379185

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998035343A Expired - Fee Related CN1249053C (zh) 1998-03-05 1999-02-25 抗溃疡药物硝酸盐

Country Status (19)

Country Link
US (1) US6503929B1 (https=)
EP (1) EP1068196B1 (https=)
JP (1) JP2002505328A (https=)
KR (1) KR20010041522A (https=)
CN (1) CN1249053C (https=)
AT (1) ATE273297T1 (https=)
AU (1) AU752919B2 (https=)
BR (1) BR9908428A (https=)
CA (1) CA2322493A1 (https=)
DE (1) DE69919341T2 (https=)
DK (1) DK1068196T3 (https=)
ES (1) ES2226357T3 (https=)
HU (1) HUP0100853A3 (https=)
IL (1) IL137721A0 (https=)
IT (1) IT1299198B1 (https=)
PT (1) PT1068196E (https=)
RU (1) RU2228331C2 (https=)
SI (1) SI1068196T1 (https=)
WO (1) WO1999045004A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
AU772188B2 (en) 1998-11-17 2004-04-08 Nitromed, Inc. Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
CA2393724A1 (en) 1999-12-23 2001-06-28 Nitromed, Inc. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
IT1317735B1 (it) * 2000-01-26 2003-07-15 Nicox Sa Sali di agenti antimicrobici.
SE0002476D0 (sv) 2000-06-30 2000-06-30 Astrazeneca Ab New compounds
JP4092203B2 (ja) 2000-12-21 2008-05-28 ニトロメッド,インク. 新規のシクロオキシゲナーゼ2選択的阻害剤としての置換アリール化合物、組成物、および使用方法
US7129161B2 (en) * 2001-07-19 2006-10-31 Trikon Holdings Limited Depositing a tantalum film
WO2003103602A2 (en) 2002-06-11 2003-12-18 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
AU2003279622A1 (en) 2002-06-28 2004-01-19 Nitromed, Inc. Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use
CA2491127A1 (en) 2002-07-03 2004-01-15 Nitromed, Inc. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
AU2003261281A1 (en) 2002-07-29 2004-02-16 Nicox S.A. Cyclooxygenase- 2 selective inhibitors, compositions and methods of use
WO2004012659A2 (en) * 2002-08-01 2004-02-12 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
RU2304967C2 (ru) * 2005-05-26 2007-08-27 Государственное общеобразовательное учреждение высшего профессионального образования Казанский государственный медицинский университет Способ лечения язвенной болезни желудка и двенадцатиперстной кишки

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1397436A (en) * 1972-09-05 1975-06-11 Smith Kline French Lab Heterocyclic n-cyanoguinidines
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4375547A (en) * 1980-10-02 1983-03-01 Eli Lilly And Company N-Methyl-N'-2-([(2-dimethylaminomethyl)-4-thiazolyl]methylthio)ethyl 2-nitro-1,1-ethenediamine
EP0224612A1 (de) 1985-12-05 1987-06-10 HEUMANN PHARMA GMBH & CO Verfahren zur Herstellung von N-Cyano-N'-methyl-N"[2-[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]guanidin
ES2053462T3 (es) * 1987-04-06 1994-08-01 Heumann Pharma Gmbh & Co Procedimiento para la produccion de derivados de nitroetano.
TW205041B (https=) * 1989-08-07 1993-05-01 Fujisawa Pharmaceutical Co

Also Published As

Publication number Publication date
HUP0100853A3 (en) 2003-01-28
JP2002505328A (ja) 2002-02-19
DE69919341T2 (de) 2005-09-08
HUP0100853A2 (hu) 2001-10-28
CN1291982A (zh) 2001-04-18
RU2228331C2 (ru) 2004-05-10
IL137721A0 (en) 2001-10-31
DK1068196T3 (da) 2004-11-29
AU752919B2 (en) 2002-10-03
CA2322493A1 (en) 1999-09-10
PT1068196E (pt) 2004-10-29
ATE273297T1 (de) 2004-08-15
EP1068196A1 (en) 2001-01-17
WO1999045004A1 (en) 1999-09-10
SI1068196T1 (en) 2004-12-31
US6503929B1 (en) 2003-01-07
DE69919341D1 (de) 2004-09-16
ES2226357T3 (es) 2005-03-16
IT1299198B1 (it) 2000-02-29
EP1068196B1 (en) 2004-08-11
BR9908428A (pt) 2000-10-31
AU3030399A (en) 1999-09-20
ITMI980442A1 (it) 1999-09-05
KR20010041522A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
CN1249053C (zh) 抗溃疡药物硝酸盐
CN1161351C (zh) 新型s-奥美拉唑
CN1210027C (zh) 治疗溃疡的药物组合物及其应用
ES2622356T3 (es) Formas cristalinas de tigeciclina y procesos para su preparación
CN1146558C (zh) 新的邦托拉唑盐
CN1167702C (zh) 5-[4-[2-n-甲基-n-(2-吡啶基)氨基]乙氧基]苄基]噻唑烷-2,4-二酮马来酸盐的多晶型物
CN1091635A (zh) 作为具有抗郁作用药物的2-氨基-6-正丙基-氨基-4,5,6,7-四氢苯并噻唑应用
CN1226236A (zh) 新化合物
JP2002505328A5 (https=)
JP2009143954A (ja) チアゾリジンジオン誘導体および抗糖尿病薬としてのその使用
JPS6229566A (ja) 新規グアニジノメチル安息香酸誘導体
CN1152878C (zh) 噻唑烷二酮衍生物及其作为抗糖尿病药的用途
CN1281454A (zh) 5-[4-[2-(n-甲基-n-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮马来酸盐的水合物
US8404854B2 (en) Barium salt of benzimidazole derivative
JPS60132990A (ja) セフアロスポリン誘導体
JPS6248678B2 (https=)
CN1822841A (zh) 抗冠状病毒剂
CN1471529A (zh) 噻唑烷二酮衍生物以及其作为抗糖尿病药物的应用
JP5017274B2 (ja) S−オメプラゾールストロンチウム塩またはその水和物、その製造方法、及びこれを含む医薬組成物
JP2008526782A (ja) セフジニルセシウム塩結晶
JPS5885895A (ja) セフアロスポリン誘導体および経口投与用細菌感染症治療剤
JPS635082A (ja) ベンズイミダゾ−ル、その製法および胃酸分泌抑制剤としての処方物
CN1471531A (zh) 噻唑烷酮(thiazolidinone)硝酸盐
JPH072636B2 (ja) 胃腸の細胞保護剤
HK1020959A (en) Modified form of the r(-)-n-(4,4-di(3-methylthien-2-yl)but-3-enyl)-nip acid hydrochlo-ride

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee